Moderna stock has fallen over the past four years, but shares got a boost on positive comments about AI. Is MRNA stock a buy ...

SINGAPORE: The updated JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be offered under the national vaccination programme at ...

The download size varies on both consoles by a fair bit. Here are the pre-load sizes for either console: The new GTA 5 update was released on PS5, PS4, Xbox One, Xbox Series X/S, as well as PC ...

The current public-health risk is low, but the CDC is watching the situation carefully and working with states to monitor ...

Moderna secured a $590 million package from the U.S. Health and Human Services Department to accelerate the development of its bird influenza vaccine as concerns about a bird flu pandemic in humans ...

The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country ...

Moderna receives $590M contract from HHS for mRNA-based bird flu vaccine; up 4% in after-hours trading. Read more here.

The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect ...

Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.

The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.

Is Moderna a no-brainer buy on the sell-off? I wouldn't go that far. Investors should think long and hard about the company's ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial investigating a ...